Thrombolytic Therapy in Acute Myocardial Infarction
Tóm tắt
Thrombolytic trials in acute myocardial infarction have progressively increased in size, with the GUSTO study including over 40,000 patients. New thrombolytic drugs are unlikely to lead to further major reductions in fatality, and demonstrating small differences from existing compounds would require even larger trials to establish mortality benefits. New agents may, however, have advantages, such as a greater ease of administration or a reduced cost, and the problem is how to assess such new agents in the most efficient way. The concept of equivalence as a clinical trial endpoint is discussed, and the INJECT study, comparing reteplase and streptokinase in acute myocardial infarction, is described as a prototype equivalence trial.
Tài liệu tham khảo
Schmutzler R, et al. Detsch Med Wochensch 1966;91:581.
European Working Party. Streptokinase in recent myocardial infarction: A controlled multicentre trial. Br Med 1971;3:325–331.
European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction. Streptokinase in acute myocardial infarction. N Engl J Med 1979;301:797–802.
Gruppo Italiano per lo Studio Della Streptochinasi Nell' Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–401.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349–360.
AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:545–549.
Wilcox RG, Von Der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR for the ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988;2:525–530.
EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342:767–772.
LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) Study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993;342:756–766.
GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65–71.
The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71–75.
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.
The GUSTO Investigators. An International randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.
Fibronolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311–322.
Braunwald E. The open-artery theory is alive and well -- again. N Engl J Med 1993;329:1650–1652.
Verstraete M, Bernard R, Bory M, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985;1:842–847.
The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–1622.
Ketley D, Woods KL. Impact of clinical trials on clinical practice: Example of thrombolysis for acute myocardial infarction. Lancet 1993;342:891–894.
Birkhead JS on behalf of the joint audit committee of the British Cardiac Society and a cardiology committee of Royal College of Physicians of London. Time delays in provision of thrombolytic treatment in six district hospitals. Br Med 1992;305:445–448.
Martin U, Sponer G, Strein K. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 1992;19:433–440.
Neuhaus K-L, von Essen R, Vogt A, et al. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: Results of the German Recombinant Plasminogen Activator Study. J Am Coll Cardiol 1994;24:55–60.
Tebbe U, von Essen R, Smolarz A, et al. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infaraction. Am J Cardiol 1993;72:518–524.
Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995;91:2725–2732.
Boehringer Mannheim GmbH. A randomized, open label, multicenter, angiographic study to compare the effects of 10 + 10 MU r-PA (reteplase) with front-loaded rt-PA (alteplase) in patients with acute myocardial infarction (MF4401-RAPID 2 Study). Boehringer Mannheim unpublished report OU-100 (acc. no. 7242).
International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;346:329–336.